M
Mardi Gomberg-Maitland
Researcher at University of Chicago
Publications - 136
Citations - 8427
Mardi Gomberg-Maitland is an academic researcher from University of Chicago. The author has contributed to research in topics: Pulmonary hypertension & Treprostinil. The author has an hindex of 42, co-authored 123 publications receiving 7456 citations.
Papers
More filters
Journal ArticleDOI
Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Raymond L. Benza,Dave P. Miller,Mardi Gomberg-Maitland,Robert P. Frantz,Aimee J. Foreman,Christopher S. Coffey,Adaani E. Frost,Robyn J. Barst,David B. Badesch,C. Gregory Elliott,Theodore G. Liou,Michael D. McGoon +11 more
TL;DR: This work identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation that may allow the individualization and optimization of therapeutic strategies.
Journal ArticleDOI
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.
Raymond L. Benza,Mardi Gomberg-Maitland,Dave P. Miller,Adaani E. Frost,Robert P. Frantz,Aimee J. Foreman,David B. Badesch,Michael D. McGoon +7 more
TL;DR: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH.
Journal ArticleDOI
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation
Thenappan Thenappan,Sanjiv J. Shah,Stuart Rich,Lu Tian,Stephen L. Archer,Mardi Gomberg-Maitland +5 more
TL;DR: In this article, a new survival prediction equation was developed using exponential regression analysis, where P(t) is probability of survival, t the time interval in years, A(x,y,z) = e((-1.270-0.361z)), x the mean pulmonary artery pressure, y the mean right atrial pressure and z the cardiac index.
Journal ArticleDOI
A USA-based registry for pulmonary arterial hypertension: 1982–2006
TL;DR: In this paper, the authors defined the epidemiology of Group I pulmonary arterial hypertension (PAH) in a large referral centre in the USA and evaluated all patients in a single USA practice from 1982-2006.
Journal ArticleDOI
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
Stephen L. Archer,Mardi Gomberg-Maitland,Michael L. Maitland,Stuart Rich,Joe G.N. Garcia,E. Kenneth Weir +5 more
TL;DR: The pyruvate dehydrogenase kinase inhibitor, dichloroacetate, corrects the mitochondrial abnormalities in experimental models of PAH and human cancer, causing a regression of both diseases.